Oak Grove Capital LLC Cuts Stock Position in Eli Lilly and Company $LLY

Oak Grove Capital LLC lessened its stake in Eli Lilly and Company (NYSE:LLY) by 34.7% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 25,022 shares of the company’s stock after selling 13,282 shares during the quarter. Eli Lilly and Company accounts for 2.7% of Oak Grove Capital LLC’s holdings, making the stock its 8th biggest position. Oak Grove Capital LLC’s holdings in Eli Lilly and Company were worth $19,092,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $27,000. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company during the second quarter worth about $29,000. Steph & Co. raised its position in Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the last quarter. Financial Gravity Companies Inc. bought a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $31,000. Finally, Bare Financial Services Inc boosted its position in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Jefferies Financial Group increased their price objective on shares of Eli Lilly and Company from $976.00 to $1,300.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. upped their target price on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Finally, Daiwa Securities Group increased their price target on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,229.59.

Eli Lilly and Company Stock Down 3.2%

LLY stock opened at $1,017.97 on Tuesday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The business’s fifty day moving average price is $1,051.98 and its two-hundred day moving average price is $934.28. The stock has a market capitalization of $960.31 billion, a price-to-earnings ratio of 44.36, a PEG ratio of 1.22 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. During the same quarter in the prior year, the business posted $5.32 earnings per share. The firm’s quarterly revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 30.15%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Orforglipron launch on deck — CFO said Lilly is preparing to launch its oral obesity drug in the U.S. as early as Q2 pending FDA approval, which would be a major new revenue stream if cleared. Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
• Positive Sentiment: Regulatory win in EU — CHMP backed expanded use of Olumiant for adolescents with severe alopecia areata, increasing near?term sales opportunities in immunology while an EU decision is expected soon. LLY Wins CHMP Nod for Olumiant’s Expanded Use in Alopecia Areata
• Positive Sentiment: Institutional buying noted — filings and commentary suggest smart?money accumulation during a recent pullback, which can support the stock if momentum re?accelerates. What Smart Money Loves About Lilly
• Neutral Sentiment: Industry backdrop — Zacks and other analysts flag large?cap pharma recovery and keep Lilly on watch as part of sector rebound, a contextual tailwind but not an immediate catalyst. Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
• Neutral Sentiment: Investor meetings and presentations — Lilly’s TD Cowen conference presentation (transcript) provides management color on pipeline and commercialization plans; useful for modeling but not a headline surprise. Eli Lilly and Company (LLY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• Neutral Sentiment: Analyst consensus remains constructive — coverage shows an average “Moderate Buy,” offering support but also reflecting already elevated expectations. Eli Lilly and Company (NYSE:LLY) Receives Average Recommendation of “Moderate Buy” from Analysts
• Negative Sentiment: Valuation and momentum cooling — multiple writeups note recent short?term negative returns and that shares trade at elevated multiples after a multi?year run, increasing sensitivity to any misses or slower growth. Eli Lilly (LLY) Valuation Check As Momentum Cools After Strong Multi Year Run
• Negative Sentiment: Competition and capacity — Novo Nordisk’s sizable Ireland capacity expansion is a strategic move to defend share in obesity/oral drug markets, posing competitive pressure on Lilly’s launch and pricing dynamics. Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.